Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer
Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer
复制标题
DOI：
10.1002/ijc.10187
复制
发表时间：
2002-04-01
影响因子：
6.4
通讯作者：
Teisner, B
中科院分区：
文献类型：
--
作者：
Jensen, BV;Johansen, JS;Teisner, B
我们研究的目的是检查细胞外基质稳态和侵袭性乳腺癌之间的关联，反映了由1型前胶原（PINP）的氨基末端前肽的循环浓度标记的I型胶原的合成。在154名健康女性和100名首次出现乳腺癌转移表现的患者中测量了治疗前血清PINP浓度，并与转移模式、治疗反应、进展时间和生存期相关，最短随访时间为5年。54%的患者血清PINP浓度高于健康对照组的第95百分位数，38%的患者为高PINP水平患者，其值明显超出正常范围（> 125 ng/ml）。PINP水平高的患者病情更重（p = 0.002），肿瘤负荷更高（p = 0.013），对蒽环类药物治疗的反应性更低（p = 0.0002），疾病进展时间（p = 0.00001）和死亡时间（p = 0.0006）加快。高血清PINP水平组的中位生存期不到低PINP水平组的一半（14.5 vs 32个月）。当癌症仅限于淋巴结和皮肤时，PINP水平最低，而如果癌症已扩散到肺部、骨骼、骨髓和肝脏，则PINP水平会增加。复发时高PINP水平和缺乏雌激素受体（ER）独立反映了复发后的侵袭性肿瘤行为，对进展时间和生存率有同样大的影响。具有高PINP水平和主要ER阴性肿瘤的患者中位生存期仅为6个月，22个月后无一人存活。相比之下，低PINP水平和ER阳性肿瘤患者的中位生存期为37个月，23%的患者在5年后仍然存活。侵袭性乳腺癌诱导强烈的纤维增生反应，合成I型胶原。血清PINP水平可能是一个诊断和预后的工具，表明乳腺癌的活动性，侵略性，扩展和转移，并预测结果后蒽环类药物为基础的化疗。(C)2002年威利-利斯。Inc.
The purpose of our study was to examine the association between extracellular matrix homeostasis and aggressive breast cancer as reflected by the synthesis of type I collagen marked by circulating concentration of the aminoterminal propeptide of type 1 procollagen (PINP). Pre-therapeutic serum PINP concentrations were measured in 154 healthy women and 100 patients referred with their first metastatic manifestation of breast cancer and correlated to the metastatic pattern, response to therapy, time to progression and survival with a minimal follow-up of 5 years. Fifty-four percent of the patients had serum PINP concentrations greater than the 95th percentile of the healthy controls and 38% were high PINP level patients with values clearly outside normal range (> 125 ng/ml). Patients with high PINP levels were more sick (p = 0.002), had a higher tumor burden (p = 0.013) and revealed a lower responsiveness to anthracycline-based therapy (p = 0.0002) as well as an accelerated time to disease progression (p = 0.00001) and death (p = 0.0006). Median survival in the high serum PINP level group was less than half of that in the group with low PINP level (14.5 vs. 32 months). The lowest PINP levels were seen when the cancer was restricted to the lymph node and skin and increasing PINP levels were found if the cancer had spread to the lungs to the bones, the bone marrow and the liver. High PINP level at recurrence and lack of estrogen receptors (ER) independently reflected aggressive tumor behavior after recurrence with an equal great impact on time to progression and survival. Patients with a high PINP level and primarily ER-negative tumors survived a median of only 6 months with no one alive after 22 months. By contrast patients with a low PINP level and ER-positive tumors had a median survival of 37 months and 23% were still alive after 5 years. Aggressive breast cancer induces a strong fibroproliferative response with synthesis of type I collagen. Serum PINP levels may be a diagnostic and prognostic tool that indicate breast cancer activity, aggressiveness, expansion and metastasis and a predictor of outcome after anthracycline-based chemotherapy. (C) 2002 Wiley-Liss. Inc.